June 16, 2024

Jonathan Knowles/DigitalVision through Getty Photographs

At a Look

Casgevy’s latest FDA nod marks a pivotal second in gene-editing therapies, advancing my earlier insights on CRISPR Therapeutics (NASDAQ:CRSP). Notably, CRISPR’s inventory has climbed in 2023, following hypothesis about Casgevy’sBLUE